Intensity Therapeutics rises as breast cancer drug shows early promise

Intensity Therapeutics

12/03/2026 11:40

** Shares of biotech firm Intensity Therapeutics INTS.O rise about 3.5% to $8.19 premarket

** Co says its experimental drug, INT230-6, showed encouraging early results in a small study in triple-negative breast cancer - an aggressive form with limited treatment options

** In a mid-stage study, five of seven patients given INT230-6 before standard chemo and immunotherapy had no trace of cancer at surgery vs two of six on standard treatment alone, a result linked to lower relapse risk, INTS says

** Co says patients receiving INT230-6 had fewer serious side effects than those on standard care

** Trial enrollment was paused last year after skin irritation cases; co says it has submitted a revised plan to resume the study at a lower dose

** Shares down ~77% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))